cytarabine has been researched along with ly335979 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baker, RJ; Burgess, M; Ethell, M; Ganeshaguru, K; Gerrard, G; Jones, DT; McCullough, H; Mehta, AB; Payne, E; Potter, M; Prentice, HG | 1 |
| Baer, MR; Duran, GE; Fielding, R; Lancet, JE; List, AF; Marcelletti, JF; Multani, PS; Sikic, BI | 1 |
2 trial(s) available for cytarabine and ly335979
| Article | Year |
|---|---|
Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine.
Topics: Abdominal Pain; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytarabine; Daunorubicin; Diarrhea; Dibenzocycloheptenes; Drug Resistance; Drug Screening Assays, Antitumor; Female; Flow Cytometry; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Nausea; Quinolines; Remission Induction | 2004 |
A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytarabine; Daunorubicin; Dibenzocycloheptenes; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Quinolines; Time Factors | 2009 |